Kedrion Biopharma
Loksidh Ganorkar is an experienced regulatory affairs professional currently serving as Executive Director of Regulatory Affairs at Kedrion Biopharma since February 2021. Prior to this role, Loksidh held the position of Senior Director of Regulatory & Scientific Affairs at CTI Clinical Trial and Consulting Services from September 2018 to February 2021. Loksidh's extensive background includes leadership roles at Novartis Vaccines and Diagnostics as Head of Regulatory Affairs CMC - FCC, Merck as Associate Director, and Pfizer as Principal Scientist. Loksidh earned a Ph.D. in Pharmaceutics & Pharmaceutical Chemistry from the University of Utah between January 1994 and January 1998.
This person is not in any teams
This person is not in any offices
Kedrion Biopharma
19 followers
Kedrion Biopharma is a biopharmaceutical company that collects and fractionates blood plasma to produce and distribute worldwide plasma-derived therapies for use in treating and preventing rare and serious diseases and conditions. In 2022, Kedrion joined forces with BPL (Bio Products Laboratory). Based in the United Kingdom, BPL has over 60 years of experience in the supply of high-quality plasma-derived medicines to treat rare diseases. Kedrion distributes its products in over 100 countries around the world. We have plants in Italy, Hungary, UK and North America, and plasma collection centers in the US and in the Czech Republic. With these figures we are the world’s 5th top player in the field of plasma-derived products. Our goal is to build a diverse and professional workforce, providing job opportunities for talented external candidates as well as internal employees who aim to grow with us. Because our work includes so many interests and skills – from Research to Sales; Plasma Collection to Production – there are abundant possibilities for learning and growth. Kedrion builds bridges: from donors to patients, from plasma to therapies, from challenge to hope.